Oxford’s Vaccine Enters Final Trials with 30,000 Volunteers - Trump Announces Launch Date!

Around 200 vaccines to fight the new novel coronavirus infection, are being developed from across the globe. Among them, seven are in the final stage of human trials. The vaccine developed by the University of Oxford has entered phase III clinical trials in the United States and is by far the most effective and safe vaccine, according to test reports.
The trial in the United States will be enrolling 30,000 adult volunteers at 8 sites and the AstraZeneca’s vaccine will be administered. “I am pleased to announce that AstraZeneca’s vaccine has reached Phase 3 clinical trials and has joined various vaccines that are very close to the end. In the United States, we are doing things that people thought were not possible,” US President Donald Trump was quoted saying in a press conference on Monday, by ANI.
“Trial centres across the US are recruiting up to 30,000 adults aged 18 years or over from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including those living with HIV, and who are at increased risk of infection from the SARS-CoV-2 virus,” AstraZeneca said in a statement.
Trump has also said that this paves way for the vaccine to be ready before the presidential elections which is scheduled for November 3.
The US has made arrangements with Operation Warp Seed to accelerate the manufacturing and distribution of the vaccine once it is proven to be safe and effective. The US aims to deliver 300 million doses by January 2021.
Similarly, Canada has also signed agreements with Novavax, Johson & Johnson, Moderna and Pfizer to secure millions of doses. “We’ve looked to sign agreements with many different companies because we really don’t know who will be first to develop a vaccine, and where it will come from,” Prime Minister Justin Trudeau said in a news conference. He also added ‘we need to be able to immunize as many Canadians as possible’.